A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Public ClinicalTrials.gov record NCT03383458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
Study identification
- NCT ID
- NCT03383458
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 545 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2018 (Actual)
- Primary completion
- May 27, 2026 (Actual)
- Completion
- May 27, 2031 (Estimated)
- Last update posted
- Jul 31, 2026
2018 – 2031
United States locations
- U.S. sites
- 28
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0081 | Anniston | Alabama | 36207 | — |
| Mayo Clinic in Arizona - Phoenix | Phoenix | Arizona | 85054 | — |
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85711 | — |
| Local Institution - 0135 | Los Angeles | California | 90095 | — |
| Local Institution - 0088 | Palo Alto | California | 94304 | — |
| Local Institution - 0085 | San Francisco | California | 94115 | — |
| Local Institution - 0235 | Aurora | Colorado | 80045 | — |
| Local Institution - 0267 | Miami | Florida | 33125 | — |
| Sylvester Comprehensive Cancer Center/ UMHC | Miami | Florida | 33136 | — |
| Local Institution - 0163 | Tampa | Florida | 33612 | — |
| Local Institution - 0009 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0025 | Westwood | Kansas | 66205 | — |
| Local Institution - 0086 | New Orleans | Louisiana | 70112 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Minnesota Oncology Hematology, P.A. | Minneapolis | Minnesota | 55404 | — |
| Local Institution - 0209 | St Louis | Missouri | 63110 | — |
| Local Institution - 0075 | New York | New York | 10016 | — |
| Local Institution - 0208 | New York | New York | 10029 | — |
| Local Institution - 0045 | New York | New York | 10065 | — |
| Local Institution - 0219 | White Plains | New York | 10601 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Local Institution - 0206 | Portland | Oregon | 97225 | — |
| Local Institution - 0272 | Austin | Texas | 78705 | — |
| Local Institution - 0270 | Dallas | Texas | 75246 | — |
| Local Institution - 0156 | Dallas | Texas | 75390 | — |
| Local Institution - 0273 | Tyler | Texas | 75702 | — |
| McGuire VA Medical Center | Richmond | Virginia | 23249 | — |
| Local Institution - 0154 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 156 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03383458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03383458 live on ClinicalTrials.gov.